Form 4: Balchem Corp Executive Acquires Shares and Stock Options

Frederic Boned, SVP/GM of Human Nutrition & Health at Balchem Corp, reports acquisition of common stock and stock options.

Summary

• On February 12, 2025, Frederic Boned, SVP/GM of Human Nutrition & Health at Balchem Corp, acquired 1,580 shares of common stock at $0 and 5,200 stock options with an exercise price of $159.18.
• Following the transaction, Boned directly owns 6,730 shares of common stock and indirectly owns 312 shares through a 401(k) plan.
• Boned also directly owns 5,200 stock options.
• The stock options vest over three years: 20% in Year 1, 40% in Year 2, and 40% in Year 3.
• The stock options expire on February 12, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of shares and stock options by a senior executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock to align management's interests with those of shareholders.
• Vesting schedules for stock options, such as the 20%/40%/40% over three years, are standard practice to incentivize long-term performance.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a key executive.

Key Dates